Postprandial Hypoglycemia
Conditions
Keywords
Empagliflozin, bariatric surgery, hyperinsulinemic response, SGLT2-inhibitor, insulin secretion, postbariatric hypoglycemia
Brief summary
This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
Detailed description
Postprandial hypoglycemia is a debilitating medical complication after bariatric surgery for which no approved pharmacological treatment exists. The prevalence of hypoglycemia in bariatric patients ranges from 0.5 % severe episodes up to 56 % and its symptoms range from asymptomatic to deleterious. This hypoglycemic condition is characterized by a rapid increase of plasma glucose after carbohydrate ingestion followed by an exaggerated hyperinsulinemic response. Hypoglycemia itself may lead to increased hunger, carbohydrate ingestion and following weight regain. In a placebo-controlled, randomized, double-blind, crossover study, the SGLT2-inhibitor empagliflozin statistically significantly reduced the number of symptomatic hypoglycemia (2 vs. 7 symptomatic hypoglycemic episodes; p=0.013) compared to placebo after a mixed meal test in 12 patients after Roux-en-Y gastric bypass. Empagliflozin reduced the postprandial rise in glycemia and decreased subsequent insulin secretion, underlining the postulated mechanism of action. This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
Interventions
DRUGEmpagliflozin (Jardiance®;
Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
OTHERPlacebo Control Intervention
Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
Sponsors
Boehringer Ingelheim
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Both subjects and investigators will be blinded.
Intervention model description
1:1 randomized, placebo-controlled, parallel-group double-blind superiority trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients after bariatric surgery (i.e. sleeve gastrectomy, Roux-en-Y gastric bypass, omega- loop bypass, biliopancreatic diversion) with documented hypoglycemia, i. e. \< 3.0 mmol/l and at least 5 hypoglycemic episodes per week despite dietary modification * For women with child-bearing potential, willingness to use contraceptive measures adequate to prevent pregnancy during the study * Informed Consent as documented by signature
Exclusion criteria
* Any type of diabetes mellitus according to ADA criteria * Intolerance to the study drug * Signs of current infection * Use of any drug therapy for postbariatric hypoglycemia apart from acarbose (all remaining drugs have to be discontinued four half-life times before screening phase) * Neutropenia (leukocyte count \< 1.5 × 109/L or absolute neutrophil count (ANC) \< 0.5 × 109/L) * Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females) * Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, AST/ALT \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN) * Uncontrolled congestive heart failure * Uncontrolled malignant disease * Currently pregnant or breastfeeding * Known or suspected non-compliance, drug or alcohol abuse * Meeting the criteria for vulnerability (e.g. participants incapable of judgment or participants under tutelage) * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Participation in another clinical trial using investigational drugs in the last 30 days or planned participation in the next 60 days * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of life (mental health; as assessed by the SF-36 mental health component score; MCS) | at baseline, at day 29 and at day 60 (+/- 10 days) after baseline | Change in Quality of life (mental health; as assessed by the SF-36 mental health component. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. |
| Change in Quality of life (physical health; as assessed by the SF-36 mental physical component score; PCS) | at baseline, at day 29 and at day 60 (+/- 10 days) after baseline | Change in Quality of life (physical health; as assessed by the SF-36 mental physical component score; PCS). Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. |
| Hypoglycemic events defined as glucose values below 3.0 mmol/l | at 28 days after randomization | Hypoglycemic events defined as glucose values below 3.0 mmol/l |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time below range (TBR): % of sensor glucose readings and time between 3.0 and 3.8 mmol/L) | at 28 days after randomization | Time below range (TBR): % of sensor glucose readings and time between 3.0 and 3.8 mmol/L) |
| Time in hypoglycemia: % of sensor glucose readings and time below 3.0 mmol/L | at 28 days after randomization | Time in hypoglycemia: % of sensor glucose readings and time below 3.0 mmol/L |
| Pattern of sensor glucose | at 28 days after randomization | Pattern of sensor glucose, defined as the slope of postprandial increase (calculated as the maximal rate of increase observed over 20min in the postprandial period) and decrease (calculated as the maximal rate of decrease over 20min in the postprandial period). |
| Postprandial Symptoms of hypoglycemia defined as acute onset of typical symptoms according to Edinburgh Hypoglycemia Scale along with a decreasing blood glucose level. | at 28 days after randomization | Postprandial Symptoms of hypoglycemia defined as acute onset of typical symptoms according to Edinburgh Hypoglycemia Scale (7-point Likert scale (1 = not present, 7 = very intense)) along with a decreasing blood glucose level. The postprandial period is defined as 3 hours following meal intake. |
| Mean amplitude of sensor glucose excursions (MAGE) | at 28 days after randomization | Mean amplitude of sensor glucose excursions (MAGE) |
| Total number of adverse events | up to 60 days after randomization | Total number of adverse events |
| Number of Serious adverse events | up to 60 days after randomization | Number of Serious adverse events |
| Glycemic variability | at 28 days after randomization | Glycemic variability (defined as the coefficient of variation (CV) of sensor glucose) |
| Hypoglycemia unawareness (measured by modified Clarke Score) | at 28 days after randomization | Hypoglycemia unawareness (measured by modified Clarke Score). The Clarke method comprises eight questions characterizing the participant's exposure to episodes of moderate and severe hypoglycemia. It also examines the glycemic threshold for, and symptomatic responses to, hypoglycemia. A score of four or more implies impaired awareness of hypoglycemia. |
| Fear of hypoglycemia (measured on a scale of 0 to 10) | at 28 days after randomization | Fear of hypoglycemia (measured on a scale of 0 to 10) |
Countries
Switzerland
Outcome results
None listed